Mark Montebello

937 total citations
34 papers, 574 citations indexed

About

Mark Montebello is a scholar working on Pharmacology, Epidemiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Mark Montebello has authored 34 papers receiving a total of 574 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pharmacology, 15 papers in Epidemiology and 9 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Mark Montebello's work include Cannabis and Cannabinoid Research (13 papers), Substance Abuse Treatment and Outcomes (11 papers) and Opioid Use Disorder Treatment (8 papers). Mark Montebello is often cited by papers focused on Cannabis and Cannabinoid Research (13 papers), Substance Abuse Treatment and Outcomes (11 papers) and Opioid Use Disorder Treatment (8 papers). Mark Montebello collaborates with scholars based in Australia, United Kingdom and New Zealand. Mark Montebello's co-authors include Nicholas Lintzeris, Adrian Dunlop, Iain S. McGregor, Jan Copeland, Melissa M. Norberg, Jessica Booth, David J. Allsop, Craig Sadler, Gonzalo Rivas and Peter Muhleisen and has published in prestigious journals such as SHILAP Revista de lepidopterología, American Journal of Psychiatry and Addiction.

In The Last Decade

Mark Montebello

30 papers receiving 556 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Montebello Australia	10	386	175	163	114	86	34	574
Jack Wilson Australia	10	468 1.2×	96 0.5×	158 1.0×	101 0.9×	89 1.0×	23	657
Nicolas J. Schlienz United States	17	594 1.5×	170 1.0×	192 1.2×	76 0.7×	53 0.6×	34	873
C. Jean Choi United States	12	214 0.6×	129 0.7×	177 1.1×	91 0.8×	161 1.9×	37	594
Amy L. Mahony United States	11	189 0.5×	158 0.9×	107 0.7×	219 1.9×	69 0.8×	20	452
Gonzalo Rivas Australia	6	230 0.6×	81 0.5×	136 0.8×	71 0.6×	59 0.7×	9	383
Gabriele Koller Germany	15	195 0.5×	240 1.4×	254 1.6×	92 0.8×	249 2.9×	41	803
Pamela Sabioni Canada	13	663 1.7×	153 0.9×	345 2.1×	120 1.1×	106 1.2×	19	968
Dino Zagic Australia	7	633 1.6×	126 0.7×	79 0.5×	141 1.2×	28 0.3×	11	811
Susan Quello United States	6	205 0.5×	199 1.1×	265 1.6×	162 1.4×	79 0.9×	9	792
Rachel Lees United Kingdom	11	541 1.4×	190 1.1×	96 0.6×	130 1.1×	16 0.2×	27	670

Countries citing papers authored by Mark Montebello

Since Specialization

Citations

This map shows the geographic impact of Mark Montebello's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Montebello with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Montebello more than expected).

Fields of papers citing papers by Mark Montebello

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Montebello. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Montebello. The network helps show where Mark Montebello may publish in the future.

Co-authorship network of co-authors of Mark Montebello

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Montebello. A scholar is included among the top collaborators of Mark Montebello based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Montebello. Mark Montebello is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Montebello, Mark, et al.. (2026). Feasibility Study of a Behavioral Oral Health Intervention for People With Mental Health Challenges: A Self‐Regulation Approach. Health Science Reports. 9(3). e71915–e71915.

Conway, Anna, Frederick L. Altice, Phillip Read, et al.. (2025). Factors Associated With Preferences for Opioid Agonist Therapies Among People Dependent on Opioids. Drug and Alcohol Review. 45(1). e70079–e70079.

Bayes, Adam, Mark Montebello, Jonathan Brett, et al.. (2024). Drug dependence and prescribing ketamine for treatment-resistant depression in Australia and New Zealand. Australian & New Zealand Journal of Psychiatry. 58(10). 831–838. 5 indexed citations

Black, Eleanor, Emma Black, Apo Demirkol, et al.. (2024). Sociodemographic and Health Factors of the Alcohol Treatment-seeking Population in New South Wales, Australia. Journal of Addiction Medicine. 18(6). 619–627.

Morley, Kirsten C., Henry R. Kranzler, Natasha Luquin, et al.. (2024). Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial. American Journal of Psychiatry. 181(5). 403–411. 9 indexed citations

Bhardwaj, Anjali, Michael Doyle, Mark Montebello, et al.. (2024). A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol. BMC Psychiatry. 24(1). 175–175. 8 indexed citations

Farrell, Michael, Jeyran Shahbazi, Marianne Byrne, et al.. (2024). 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial. International Journal of Drug Policy. 127. 104390–104390. 4 indexed citations

Black, Emma, Raimondo Bruno, Llewellyn Mills, et al.. (2023). Substance use, socio‐demographic characteristics, and self‐rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort study. The Medical Journal of Australia. 219(5). 218–226. 4 indexed citations

Black, Emma, Rachel Deacon, Nadine Ezard, et al.. (2022). Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016–2019. Drug and Alcohol Review. 42(2). 389–400. 2 indexed citations

10.

Valerio, Heather, Anna Conway, Maryam Alavi, et al.. (2022). Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study. International Journal of Drug Policy. 110. 103876–103876. 3 indexed citations

11.

Montebello, Mark, Meryem Jefferies, Llewellyn Mills, et al.. (2022). Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial. Drug and Alcohol Dependence. 234. 109388–109388. 4 indexed citations

12.

Brown, Amanda, Jennifer Johnston, Richard Clancy, et al.. (2021). The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients. SHILAP Revista de lepidopterología. 3(1). 33–33. 3 indexed citations

13.

Mills, Llewellyn, Nicholas Lintzeris, Raimondo Bruno, et al.. (2020). Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence. Drug and Alcohol Review. 39(4). 356–364. 8 indexed citations

14.

Lintzeris, Nicholas, Llewellyn Mills, Adrian Dunlop, et al.. (2020). Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. Drug and Alcohol Dependence. 215. 108220–108220. 25 indexed citations

15.

Lintzeris, Nicholas, Lauren A. Monds, Adrian Dunlop, et al.. (2018). Transferring Patients From Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines. Journal of Addiction Medicine. 12(3). 234–240. 23 indexed citations

16.

Bhardwaj, Anjali, David J. Allsop, Jan Copeland, et al.. (2018). Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol. BMC Psychiatry. 18(1). 140–140. 16 indexed citations

17.

Montebello, Mark & Jonathan Brett. (2015). Misuse and Associated Harms of Quetiapine and Other Atypical Antipsychotics. Current topics in behavioral neurosciences. 34. 125–139. 21 indexed citations

18.

Wong, Alexander, Mark Montebello, Melissa M. Norberg, et al.. (2013). Exercise increases plasma THC concentrations in regular cannabis users. Drug and Alcohol Dependence. 133(2). 763–767. 33 indexed citations

19.

Cruickshank, Christopher, et al.. (2008). A placebo‐controlled trial of mirtazapine for the management of methamphetamine withdrawal. Drug and Alcohol Review. 27(3). 326–333. 56 indexed citations

20.

Baillie, Andrew, et al.. (2008). Are cannabis users who participate in a randomized clinical trial different from other treatment seekers?. Journal of Substance Abuse Treatment. 36(3). 339–344. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact